TY - JOUR
T1 - A reverse Genetics and Genomics Approach to Gene Paralog Function and Disease
T2 - Myokymia and The Juxtaparanode
AU - Marafi, Dana
AU - Kozar, Nina
AU - Duan, Ruizhi
AU - Bradley, Stephen
AU - Yokochi, Kenji
AU - Al Mutairi, Fuad
AU - Waill Saadi, Nebal
AU - Whalen, Sandra
AU - Brune, Theresa
AU - Kotzaeridou, Urania
AU - Choukair, Daniela
AU - Keren, Boris
AU - Nava, Caroline
AU - Kato, Mitsuhiro
AU - Arai, Hiroshi
AU - Froukh, Tawfiq
AU - Faqeih, Eissa Ali
AU - AlAsmari, Ali M
AU - Saleh, Mohammed M
AU - Vairo, Filippo Pinto e
AU - Pichurin, Pavel N
AU - Klee, Eric W
AU - Schmitz, Christopher T
AU - Grochowski, Christopher M
AU - Mitani, Tadahiro
AU - Herman, Isabella
AU - Calame, Daniel
AU - Faith, Jawid M
AU - Du, Haowei
AU - Coban-Akdemir, Zeynep
AU - Pehlivan, Davut
AU - Jhangiani, Shalini N
AU - Gibbs, Richard A
AU - Miyatake, Satoko
AU - Matsumoto, Naomichi
AU - Wagstaff, Laura J
AU - Posey, Jennifer E
AU - Lupski, James R
AU - Meijer, Dies
AU - Wagner, Matias
N1 - Funding Information:
We thank the families for their participation in the study. M. Jaegle, A. Aunin, and S. Driegen are thanked for generation of the Lgi3 knock-out mouse line. This study was supported by the U.S. National Human Genome Research Institute and National Heart, Lung, and Blood Institute to the Baylor-Hopkins Center for Mendelian Genomics (BHCMG, UM1 HG006542), NHGRI Baylor College of Medicine Genomics Research Elucidates Genetics of Rare (BCM-GREGoR; U01 HG011758), U.S. National Institute of Neurological Disorders and Stroke (NINDS) (R35NS105078), National Institute of General Medical Sciences (NIGMS, R01GM106373), the Muscular Dystrophy Association (MDA; 512848), and Spastic Paraplegia Foundation to J.R.L. D.M. was supported by a Medical Genetics Research Fellowship Program through the United States National Institutes of Health (T32 GM007526-42). J.E.P. was supported by NHGRI K08 HG008986. This study was also supported in part by the JSPS KAKENHI (grant number JP20K07907 to S.M.) and the Japan Agency for Medical Research and Development under grant numbers JP21ek0109486, JP21ek0109549, JP21cm0106503, and JP21ek0109493 to N.M. D.P. is supported by International Rett Syndrome Foundation (IRSF grant #3701-1). D.G.C. is supported by NIH Brain Disorder and Development training grant (T32 NS043124-19) and Muscular Dystrophy Association Development grant (873841). T.F. was funded by Philadelphia University, Amman, Jordan. E.A.F. was funded by King Fahad Medical City Research Centre/IRF 019-052. N.K. S.B. and D. Meijer were supported by the UKRI Biotechnology and Biological Sciences Research Council (BBSRC) grant number BB/N015142/1 (to D. Meijer), grant number BB/T00875X/1 (S.B.), and grant number BB/M010996/1 (N.K.). J.R.L. has stock ownership in 23andMe; is a paid consultant for Regeneron Genetics Center; and is a co-inventor on multiple United States and European patents related to molecular diagnostics for inherited neuropathies, eye diseases, genomic disorders, and bacterial genomic fingerprinting. The Department of Molecular and Human Genetics at Baylor College of Medicine receives revenue from clinical genetic testing conducted at Baylor Genetics (BG); J.R.L. serves on the Scientific Advisory Board (SAB) of BG.
Funding Information:
We thank the families for their participation in the study. M. Jaegle, A. Aunin, and S. Driegen are thanked for generation of the Lgi3 knock-out mouse line. This study was supported by the U.S. National Human Genome Research Institute and National Heart, Lung, and Blood Institute to the Baylor-Hopkins Center for Mendelian Genomics (BHCMG, UM1 HG006542 ), NHGRI Baylor College of Medicine Genomics Research Elucidates Genetics of Rare (BCM-GREGoR; U01 HG011758 ), U.S. National Institute of Neurological Disorders and Stroke (NINDS) ( R35NS105078 ), National Institute of General Medical Sciences (NIGMS, R01GM106373 ), the Muscular Dystrophy Association (MDA; 512848 ), and Spastic Paraplegia Foundation to J.R.L. D.M. was supported by a Medical Genetics Research Fellowship Program through the United States National Institutes of Health ( T32 GM007526-42 ). J.E.P. was supported by NHGRI K08 HG008986 . This study was also supported in part by the JSPS KAKENHI (grant number JP20K07907 to S.M.) and the Japan Agency for Medical Research and Development under grant numbers JP21ek0109486 , JP21ek0109549 , JP21cm0106503 , and JP21ek0109493 to N.M. D.P. is supported by International Rett Syndrome Foundation (IRSF grant #3701-1 ). D.G.C. is supported by NIH Brain Disorder and Development training grant ( T32 NS043124-19 ) and Muscular Dystrophy Association Development grant ( 873841 ). T.F. was funded by Philadelphia University , Amman, Jordan. E.A.F. was funded by King Fahad Medical City Research Centre/ IRF 019-052 . N.K., S.B., and D. Meijer were supported by the UKRI Biotechnology and Biological Sciences Research Council (BBSRC) grant number BB/N015142/1 (to D. Meijer), grant number BB/T00875X/1 (S.B.), and grant number BB/M010996/1 (N.K.).
Publisher Copyright:
© 2022
PY - 2022/8/9
Y1 - 2022/8/9
N2 - The leucine-rich glioma-inactivated (LGI) family consists of four highly conserved paralogous genes, LGI1-4, that are highly expressed in mammalian central and/or peripheral nervous systems. LGI1 antibodies are detected in subjects with autoimmune limbic encephalitis and peripheral nerve hyperexcitability syndromes (PNHSs) such as Isaacs and Morvan syndromes. Pathogenic variations of LGI1 and LGI4 are associated with neurological disorders as disease traits including familial temporal lobe epilepsy and neurogenic arthrogryposis multiplex congenita 1 with myelin defects, respectively. No human disease has been reported associated with either LGI2 or LGI3. We implemented exome sequencing and family-based genomics to identify individuals with deleterious variants in LGI3 and utilized GeneMatcher to connect practitioners and researchers worldwide to investigate the clinical and electrophysiological phenotype in affected subjects. We also generated Lgi3-null mice and performed peripheral nerve dissection and immunohistochemistry to examine the juxtaparanode LGI3 microarchitecture. As a result, we identified 16 individuals from eight unrelated families with loss-of-function (LoF) bi-allelic variants in LGI3. Deep phenotypic characterization showed LGI3 LoF causes a potentially clinically recognizable PNHS trait characterized by global developmental delay, intellectual disability, distal deformities with diminished reflexes, visible facial myokymia, and distinctive electromyographic features suggestive of motor nerve instability. Lgi3-null mice showed reduced and mis-localized Kv1 channel complexes in myelinated peripheral axons. Our data demonstrate bi-allelic LoF variants in LGI3 cause a clinically distinguishable disease trait of PNHS, most likely caused by disturbed Kv1 channel distribution in the absence of LGI3.
AB - The leucine-rich glioma-inactivated (LGI) family consists of four highly conserved paralogous genes, LGI1-4, that are highly expressed in mammalian central and/or peripheral nervous systems. LGI1 antibodies are detected in subjects with autoimmune limbic encephalitis and peripheral nerve hyperexcitability syndromes (PNHSs) such as Isaacs and Morvan syndromes. Pathogenic variations of LGI1 and LGI4 are associated with neurological disorders as disease traits including familial temporal lobe epilepsy and neurogenic arthrogryposis multiplex congenita 1 with myelin defects, respectively. No human disease has been reported associated with either LGI2 or LGI3. We implemented exome sequencing and family-based genomics to identify individuals with deleterious variants in LGI3 and utilized GeneMatcher to connect practitioners and researchers worldwide to investigate the clinical and electrophysiological phenotype in affected subjects. We also generated Lgi3-null mice and performed peripheral nerve dissection and immunohistochemistry to examine the juxtaparanode LGI3 microarchitecture. As a result, we identified 16 individuals from eight unrelated families with loss-of-function (LoF) bi-allelic variants in LGI3. Deep phenotypic characterization showed LGI3 LoF causes a potentially clinically recognizable PNHS trait characterized by global developmental delay, intellectual disability, distal deformities with diminished reflexes, visible facial myokymia, and distinctive electromyographic features suggestive of motor nerve instability. Lgi3-null mice showed reduced and mis-localized Kv1 channel complexes in myelinated peripheral axons. Our data demonstrate bi-allelic LoF variants in LGI3 cause a clinically distinguishable disease trait of PNHS, most likely caused by disturbed Kv1 channel distribution in the absence of LGI3.
KW - LGI3
KW - peripheral nerve hyperexcitability syndromes
KW - facial myokymia
KW - neurobiology of disease
KW - genomic rearrangement
KW - gene and genome instability
KW - bi-allelic variation
KW - KCNA
KW - multi-exonic CNV
KW - potassium channel complexes
U2 - 10.1016/j.ajhg.2022.07.006
DO - 10.1016/j.ajhg.2022.07.006
M3 - Article
SN - 0002-9297
VL - 109
JO - American Journal of Human Genetics
JF - American Journal of Human Genetics
ER -